Replication-competent recombinant herpes simplex virus type 1 (HSV-1) comprising deletions in the ICP6 and IR regions
AssigneeSungkwang Medical Foundation
InventorsKyung Ju Choi, Joo Hang Kim
Life of this patent
Estimating the term…
Abstract
A recombinant herpes simplex virus type 1 (HSV-1), a recombinant HSV-1 vector, and a method of preparing the recombinant HSV-1, may enable easy genetic modification, as a relatively large foreign gene may be inserted or various foreign genes may be inserted simultaneously, as ICP6 and IR regions are simultaneously deleted. These may be used in cancer treatment as an oncolytic virus that is safe, while having an excellent effect in killing cancer cells.
Claims15
A recombinant herpes simplex virus type 1 (HSV-1) strain KOS, comprising:
- an HSV-1 genome, in which an infected-cell protein 6 (ICP6) region among genomic regions of HSV-1 is deleted, and the nucleotide sequence of SEQ ID NO:2 among nucleotide sequences of the internal repeat (IR) region between a unique long (UL) region and a unique short (US) region is deleted,
- wherein the recombinant HSV-1 is replication-competent and is an oncolytic virus that activates immune cells by exposing antigens of cancer cells by specifically killing cancer cells,
- wherein the simultaneous deletion of ICP6 and a nucleotide sequence of SEQ ID NO:2 enhances the ability to selectively kill cancer cells, and
- wherein the cancer is lung cancer or glioma.
A method of preparing a recombinant HSV-1 strain KOS, wherein the recombinant HSV-1 is replication-competent and is an oncolytic virus that activates immune cells by exposing antigens of cancer cells by specifically killing cancer cell, the method comprising:
- preparing a recombinant HSV-1 vector comprising a genome nucleotide sequence of HSV-1 strain KOS, in which an ICP6 region and the nucleotide sequence of SEQ ID NO:2 among nucleotide sequences of the IR region are deleted;
- and
- transfecting cells with the vector to obtain a recombinant HSV-1,
- wherein the simultaneous deletion of ICP6 and a nucleotide sequence of SEQ ID NO:2 enhances the ability to selectively kill cancer cells, and
- wherein the cancer is lung cancer or glioma.
Dependencies are inferred from the claim text.